"SUBJECT_ID"	"GenSig:sen"	"GenSig:res"	"Feature.sensitive"	"Feature.resistant"	"dGensig"	"mySlope"	"TEST_SET"	"PatientID"	"BGUSCT"	"Erstatus"	"Prstatus"	"HER2status"	"TreatmentArm"	"DrugTreatment"	"Age"	"ECOG"	"Inflammatory"	"Menopausalstatus"	"pCR_patient"	"pCR_Breast"	"label"	"senlabel"
"GSM1232994"	0.592726974637515	0.101446940375557	7800	16017	0.383375464368512	0.859526917635137	1	"patid: 191"	"bgus.ct: 30.75"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 55"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1232996"	0.241339901152386	0.271555395532014	7800	16017	0.00601436776627488	0.859526917635137	1	"patid: 131"	"bgus.ct: 30.09"	"er: ER+"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 73"	"ecog: 1"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1232997"	0.635831069235533	0.664645353754643	7800	16017	0.0489526782917421	0.859526917635137	1	"patid: 91"	"bgus.ct: 31.9"	"er: ER+"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 49"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1232998"	0.0588126770045721	0.257088165757727	7800	16017	-0.122977222023737	0.859526917635137	1	"patid: 151"	"bgus.ct: 30.98"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 47"	"ecog: 1"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1232999"	0.385668431183877	0.137773360380965	7800	16017	0.20267126361296	0.859526917635137	1	"patid: 71"	"bgus.ct: 31.62"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 60"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233000"	1	0.246183617084726	7800	16017	0.597891923272986	0.859526917635137	1	"patid: 111"	"bgus.ct: 29.22"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 53"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233001"	0.807732139781821	0.350814082748823	7800	16017	0.383881590896324	0.859526917635137	1	"patid: 41"	"bgus.ct: 29.34"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 44"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233004"	0.516549569792424	0.871968886802677	7800	16017	-0.176646263888499	0.859526917635137	1	"patid: 81"	"bgus.ct: 31.96"	"er: ER+"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 67"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233006"	0.318828603364347	0.125876526358877	7800	16017	0.15973719172418	0.859526917635137	1	"patid: 21"	"bgus.ct: 31.02"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 51"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233008"	0.397245209290077	0.215867064218325	7800	16017	0.160546604417283	0.859526917635137	1	"patid: 381"	"bgus.ct: 30.27"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 64"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233009"	0.569343010065318	0.346949585740527	7800	16017	0.205615213805414	0.859526917635137	1	"patid: 321"	"bgus.ct: 30.67"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 50"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233011"	0.0452357902016521	0.31336566590905	7800	16017	-0.169956956517065	0.859526917635137	1	"patid: 331"	"bgus.ct: 30.94"	"er: ER+"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 59"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233012"	0.327491236726482	1	7800	16017	-0.403475925620302	0.859526917635137	1	"patid: 301"	"bgus.ct: 31.75"	"er: ER+"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 47"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233017"	0.732119001385424	0.0693953393344615	7800	16017	0.509977446135315	0.859526917635137	1	"patid: 221"	"bgus.ct: 29.79"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 60"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233020"	0.638679879609829	0.452780321716846	7800	16017	0.189213730635661	0.859526917635137	1	"patid: 261"	"bgus.ct: 29.5"	"er: ER+"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 59"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233022"	0.924383386357329	0.303445072354754	7800	16017	0.503222210077867	0.859526917635137	1	"patid: 241"	"bgus.ct: 31.02"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 54"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233023"	0.548195198435757	0.615293276416127	7800	16017	0.014662230558354	0.859526917635137	1	"patid: 421"	"bgus.ct: 31.45"	"er: ER+"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 51"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233026"	0.310942862082969	0.143514096956105	7800	16017	0.142260190295537	0.859526917635137	1	"patid: 401"	"bgus.ct: 32.32"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 48"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233027"	0.47947039419932	0.0692297745460548	7800	16017	0.318486129499776	0.859526917635137	1	"patid: 511"	"bgus.ct: 30.04"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 52"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233028"	0.564927875740873	0.441429283182512	7800	16017	0.140681955907503	0.859526917635137	1	"patid: 451"	"bgus.ct: 31.35"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 64"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233033"	0.377415133425024	0.306313913539445	7800	16017	0.0865519759603154	0.859526917635137	1	"patid: 91"	"bgus.ct: 33.46"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 48"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233034"	0.516210459017793	0.191186332457839	7800	16017	0.26685310795959	0.859526917635137	1	"patid: 101"	"bgus.ct: 30.27"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 53"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233036"	0.46906906038232	0.740934856915885	7800	16017	-0.127241397224197	0.859526917635137	1	"patid: 81"	"bgus.ct: 30.56"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 44"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233037"	0.611692817648254	0.522979710338791	7800	16017	0.122989475315929	0.859526917635137	1	"patid: 91"	"bgus.ct: 31.75"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 39"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233040"	0.584477914730102	0.398894838821858	7800	16017	0.18323332780514	0.859526917635137	1	"patid: 141"	"bgus.ct: 33.63"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 48"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233041"	0.344563238899668	0.23300324627334	7800	16017	0.109424642898922	0.859526917635137	1	"patid: 121"	"bgus.ct: 34.27"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 46"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233045"	0.528047003700273	0.146335264673497	7800	16017	0.305064906407553	0.859526917635137	1	"patid: 31"	"bgus.ct: 30.92"	"er: ER+"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 35"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233047"	0.229371115031568	0.41799153586052	7800	16017	-0.0985142211216487	0.859526917635137	1	"patid: 491"	"bgus.ct: 32.93"	"er: ER+"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 35"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233048"	0.634598496202704	0.200176363908076	7800	16017	0.350774160243896	0.859526917635137	1	"patid: 441"	NA	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 47"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233050"	0.487347470732351	0.269474965689755	7800	16017	0.193933383751465	0.859526917635137	1	"patid: 421"	"bgus.ct: 33.56"	"er: ER-"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 50"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233052"	0.661643189102907	0.260260770236407	7800	16017	0.332118842644672	0.859526917635137	1	"patid: 301"	"bgus.ct: 33.53"	"er: ER-"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 41"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233053"	0.585704605039882	0.649700355515235	7800	16017	0.0206802891974697	0.859526917635137	1	"patid: 31"	"bgus.ct: 31.82"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 54"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233055"	0.314838715427527	0.345756213761387	7800	16017	0.0133865719906726	0.859526917635137	1	"patid: 71"	"bgus.ct: 34.81"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 52"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233056"	0.210235615861441	0.46217075566037	7800	16017	-0.141823340476192	0.859526917635137	1	"patid: 91"	"bgus.ct: 34.41"	"er: ER+"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 56"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233058"	0.331727766800153	0.229521079030378	7800	16017	0.101960493340615	0.859526917635137	1	"patid: 801"	"bgus.ct: 32.11"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 45"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233059"	0.519293279472141	0.468047618145753	7800	16017	0.0887236786055118	0.859526917635137	1	"patid: 861"	"bgus.ct: 32.03"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 57"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233061"	0.368774195733917	0.690449502503595	7800	16017	-0.17039324416924	0.859526917635137	1	"patid: 661"	"bgus.ct: 32.34"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 45"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233063"	0.0527849755927504	0.217164506609953	7800	16017	-0.101524846057689	0.859526917635137	1	"patid: 891"	"bgus.ct: 33.73"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 37"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233065"	0.35009248991493	0.350223987372135	7800	16017	0.0372094713270523	0.859526917635137	1	"patid: 631"	"bgus.ct: 30.06"	"er: ER-"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 42"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233066"	0.0841396588930224	0.366554673661092	7800	16017	-0.175124071145274	0.859526917635137	1	"patid: 551"	"bgus.ct: 32.48"	"er: ER+"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 35"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233070"	0.256264574442746	0.126166327536495	7800	16017	0.112102074420532	0.859526917635137	1	"patid: 41"	"bgus.ct: 30.95"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 55"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233071"	0.683784443510485	0.352032779106187	7800	16017	0.289089915711976	0.859526917635137	1	"patid: 161"	"bgus.ct: 29.49"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 41"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233074"	0.295099094435669	0.670023177349888	7800	16017	-0.21295112748618	0.859526917635137	1	"patid: 121"	"bgus.ct: 29.71"	"er: ER+"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 55"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233076"	0.225366152856364	0.21915075487317	7800	16017	0.0280595501740156	0.859526917635137	1	"patid: 51"	"bgus.ct: 30.42"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 45"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233077"	0	0.531492060673048	7800	16017	-0.346444069074569	0.859526917635137	1	"patid: 61"	"bgus.ct: 0"	"er: ER+"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 58"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233080"	0.554127808102495	0.204026658733913	7800	16017	0.287238456274029	0.859526917635137	1	"patid: 61"	"bgus.ct: 33.24"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 58"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233081"	0.271122168527686	0.665110974431964	7800	16017	-0.227932393698302	0.859526917635137	1	"patid: 141"	"bgus.ct: 32"	"er: ER+"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 46"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233084"	0.474537540116176	0.415581430673023	7800	16017	0.0889817956672257	0.859526917635137	1	"patid: 81"	"bgus.ct: 33.4"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 36"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233087"	0.277680714766781	0.112480410673838	7800	16017	0.137264205170599	0.859526917635137	1	"patid: 11"	"bgus.ct: 32.98"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 52"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: RD"	0	"res"	"other"
"GSM1233088"	0.454128443548352	0.236233661568727	7800	16017	0.190409097497289	0.859526917635137	1	"patid: 301"	"bgus.ct: 31.52"	"er: ER-"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 41"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233089"	0.181548313804179	0.277671791051697	7800	16017	-0.0433162002495758	0.859526917635137	1	"patid: 351"	"bgus.ct: 30.93"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 49"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233090"	0.426425579252666	0.394494451768044	7800	16017	0.0662406761562443	0.859526917635137	1	"patid: 21"	"bgus.ct: 32.69"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 56"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233092"	0.201246345093492	0	7800	16017	0.152617687643849	0.859526917635137	1	"patid: 221"	"bgus.ct: 30.66"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 56"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233094"	0.341645438893753	0.140266931718942	7800	16017	0.167660483644373	0.859526917635137	1	"patid: 141"	"bgus.ct: 31.51"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 60"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233097"	0.398844286911014	0.199143523400662	7800	16017	0.172660240898723	0.859526917635137	1	"patid: 61"	"bgus.ct: 31.26"	"er: ER-"	"pr: PR+"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 58"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233099"	0.0921881779261804	0.161293122995992	7800	16017	-0.0352241217136089	0.859526917635137	1	"patid: 101"	"bgus.ct: 31.83"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 52"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233100"	0.214214784818243	0.0361940995813519	7800	16017	0.138859957586407	0.859526917635137	1	"patid: 111"	"bgus.ct: 32.87"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 46"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233104"	0.630654071292638	0.401456833669711	7800	16017	0.216581601963054	0.859526917635137	1	"patid: 31"	"bgus.ct: 30.83"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 42"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233106"	0.514133121890985	0.172183389464172	7800	16017	0.277664478826186	0.859526917635137	1	"patid: 101"	"bgus.ct: 34.21"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 26"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233111"	0.973718579154171	0.545817170809424	7800	16017	0.382650037569909	0.859526917635137	1	"patid: 21"	"bgus.ct: 31.96"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 76"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233112"	0.269540045430378	0.503615179162557	7800	16017	-0.123863926432042	0.859526917635137	1	"patid: 51"	"bgus.ct: 33.35"	"er: ER+"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 58"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: RD"	0	"res"	"other"
"GSM1233122"	0.238762356086524	0.0942102732317778	7800	16017	0.11965905883527	0.859526917635137	1	"patid: 21"	"bgus.ct: 29.5"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 38"	"ecog: 0"	"inflammatory.brca: yes"	"menopausal.status: pre"	"pcr: pCR"	1	"sen"	"sen"
"GSM1233146"	0.145786546970773	0.0692950290816999	7800	16017	0.0653902674612025	0.859526917635137	1	"patid: 161"	"bgus.ct: 26.6425"	"er: ER-"	"pr: PR-"	"her2: HER2+"	"arm: HER2+ CT H"	"treatment: neoadjuvant doxorubicin/paclitaxel (AT) followed by cyclophosphamide/methotrexate/fluorouracil (CMF) + Trastuzumab for 1 year"	"age: 58"	"ecog: 0"	"inflammatory.brca: no"	"menopausal.status: post"	"pcr: pCR"	1	"sen"	"sen"
